Status:
RECRUITING
Safety and Efficacy of Xalkori ROS1
Lead Sponsor:
Pfizer
Conditions:
Non-small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Brief Summary
The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the LPD (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in thi...
Eligibility Criteria
Inclusion
- patients with unresectable progressive/recurrent NSCLC who are naive to XALKORI and whose tumor is ROS1 gene positive
Exclusion
- Patients with past history of hypersensitivity to any of the ingredients of XALKORI
Key Trial Info
Start Date :
October 25 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 26 2027
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT03375242
Start Date
October 25 2017
End Date
March 26 2027
Last Update
June 25 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Tokyo
Tokyo, Japan